This document discusses Targovax's strategy for outsourcing clinical manufacturing and quality control activities. As a virtual biotech company, Targovax outsources all development, manufacturing, and testing of its three investigational medicinal products - a peptide vaccine (TG), recombinant GM-CSF, and an oncolytic virus (ONCOS-102). The document describes Targovax's current contract manufacturing organizations for clinical supply and its plans to select new partners to support late-stage clinical trials and commercialization. A multi-stage selection process is outlined involving screening of potential partners, requests for proposals, audits, and selection of organizations meeting Targovax's regulatory and capacity requirements.